The Ensign Group Stock Earnings Reports

Key points for investors:

- Strong operational performance: Same-store and transitioning occupancy reached record highs (84.3% and 85.1%). Same-store skilled revenue and days rose ~9.6% and 5.1% year-over-year; Medicare revenue increased ~9.8%.

- Skilled-mix and payer trends: Managed care and Medicare census increased sequentially (managed care +6.2% and Medicare +8.3% Q4→Q1). Management sees higher-acuity admissions and believes payer scrutiny/refined utilization is not reducing overall demand for skilled nursing.

- Clinical quality & talent: Same-store facilities significantly outperformed peers on CMS survey and quality measures; 85% of operations are 4- or 5-star. Director of nursing turnover down 32% over two years; improvements in turnover, wage stability and reduced agency reliance.

- M&A and growth: Accelerated add of operations (22 recent operations; 71 closed since 2024), including a sizable Texas portfolio and other strategic/high-quality assets. Standard Bearer REIT added 21 assets, now 173 properties; rental revenue $36.1M this quarter.

- Financial results and balance sheet: Q1 GAAP diluted EPS $1.67 (+21.9%), adjusted EPS $1.85 (+21.7%). Consolidated revenue $1.4B (+18.4%). Cash $539.5M; operating cash flow $100.2M. Lease-adjusted net debt/EBITDA 1.73x after acquisitions. >$1B combined liquidity (cash + available capacity).

- Guidance raised: 2026 earnings guidance increased to $7.48–$7.62 per diluted share (from $7.41–$7.61) and revenue guidance to $5.81B–$5.86B. Midpoint implies ~15% growth vs. 2025 and 37% vs. 2024.

- Capital allocation and discipline: Continued acquisitions funded from strong liquidity; 155 of 179 owned assets debt-free. Management emphasizes owning where possible, otherwise attractive long-term leases.

- Execution items to watch: Integration of recent turnaround acquisitions (expected to lift revenue sooner than EPS), ERP implementation (go-live Jan 1; early-stage benefits expected later), continued pilot programs (e.g., I-SNPs, specialty units, behavioral health in some markets).

- Risks and uncertainty: Seasonality (Q2/Q3 softer skilled mix), state Medicaid budget pressures, variation in reimbursement, acquisition timing/transition effects, regulatory/clinical review dynamics.

Takeaway: Ensign reported robust organic and acquisition-driven growth, improved clinical metrics and stable leverage, and raised full-year guidance. The company emphasizes high-quality outcomes, local leadership, continued M&A (including higher-quality/newer construction assets), and ample liquidity to fund growth—while noting acquisition transitions can depress near-term EPS versus revenue.